Evaluating the effectiveness and safety of different platinum-based chemotherapy regimens given after surgery for the treatment of early-stage resected NSCLC.

This study evaluated the effectiveness and safety of different platinum-based chemotherapy regimens given after surgery for the treatment of early-stage resected non-small cell lung cancer (NSCLC). The authors concluded that the combination of cisplatin (Platinol)-vinorelbine (Nevelbine) improved the outcomes of these patients. Also, the authors suggested that this analysis may provide some guiding significance for doctors when determining the optimal chemotherapy regimen after surgery.

NSCLC is the most common form of lung cancer. It is responsible for around 85% of all lung cancer cases worldwide. Standard treatment for early-stage NSCLC involves surgical removal of tumors, chemotherapy, and radiotherapy.

Standard chemotherapy regimens usually contain drugs such as carboplatin (Paraplatin), which belongs to the class of drugs called platinum analogs. These chemotherapeutic drugs block the formation of new cancer cells, thus delaying tumor growth and spread. However, the effectiveness and safety of different platinum-based chemotherapy regimens given after surgery for the treatment of early-stage resected NSCLC are still unknown.

This study analyzed 20 other studies that involved 5483 patients with early-stage NSCLC. Patients were divided into 2 groups- the platinum-based chemotherapy group and the observation-control group. The average follow-up time ranged from 20.2 months to 116 months.

Patients in the platinum-based chemotherapy group were 33% more likely to survive without cancer coming back (relapse) than patients in the observation group. Patients in the platinum-based chemotherapy group were 20% more likely to have a better overall survival than patients in the observation group.

Patients treated with cisplatin plus vinorelbine were 37% more likely to survive without cancer relapse than patients in the observation group. Patients treated with cisplatin plus vinorelbine were 26% more likely to have a better overall survival than patients in the observation group.

Treatment-related side effects were similar between the 2 groups. The most common side effects were blood-related and nausea/vomiting.

This study concluded that the combination of cisplatin-vinorelbine given after surgery improved the outcomes of patients with early-stage resected NSCLC. The authors also suggested that their analysis may provide some guiding significance for doctors when determining the optimal chemotherapy regimen after surgery.

This study looked back in time at medical records. This study did not include any targeted therapy in its analysis.